Scholarlink

<p>Acesulfame potassium (Ace-K) is a low-calorie sweetener (LCS) widely used as an ingredient in foods and beverages and an excipient in pediatric medicines. While prior candidate gene studies have established that genetic variants in bitter taste receptor (<i>TAS2R</i>) genes are associated with variation in the taste of Ace-K, we sought to identify genetic contributions to its taste using a genome-wide association study (GWAS) of 141 adult panelists who rated the taste of an aqueous solution of Ace-K using the general labelled magnitude scale (gLMS) and its palatability using the hedonic gLMS. To determine whether GWAS-identified associations with Ace-K generalized to a more complex stimulus, panelists also rated the taste of a pediatric medicine that contains Ace-K as an excipient (Children’s Motrin™). We identified that a <i>TAS2R</i>-containing locus on chromosome 12 was associated with bitterness ratings of Ace-K (p-values &lt; 5 × 10<sup>− 8</sup>), and the lead SNP rs2708381 in this locus was associated with the sweetness intensity of Children’s Motrin™ (p-value = 0.001). SNP rs2708381 was also associated with perceived intensity ratings of another LCS, neohesperidine dihydrochalcone, in a replication GWAS of 1,757 panelists (p-value = 0.002). A locus within the gene <i>ELMO1</i>, which encodes engulfment and cell motility protein 1, was associated with hedonic ratings of Ace-K (p-values &lt; 5 × 10<sup>− 8</sup>), and no genome-wide significant signals were observed for sweetness ratings. These findings identify a novel genetic locus containing <i>TAS2R</i> genes that contributes to personal differences in the taste of Ace-K, which may impact the acceptance of medicines, food, and beverages containing Ace-K.</p><p><i>Clinical trials registration</i>: Sensory evaluation of the taste of pediatric medicines (MEDTASTE); clinical trials registry number NCT03627351, registered on 13 August 2018.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genome-wide association study of the taste and hedonic ratings of the low-calorie sweetener acesulfame potassium

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Mengyuan Kan,
  • Luis R. Saraiva,
  • Liang-Dar Hwang,
  • Elizabeth D. Lowenthal,
  • Blanca E. Himes,
  • Julie A. Mennella

摘要

Acesulfame potassium (Ace-K) is a low-calorie sweetener (LCS) widely used as an ingredient in foods and beverages and an excipient in pediatric medicines. While prior candidate gene studies have established that genetic variants in bitter taste receptor (TAS2R) genes are associated with variation in the taste of Ace-K, we sought to identify genetic contributions to its taste using a genome-wide association study (GWAS) of 141 adult panelists who rated the taste of an aqueous solution of Ace-K using the general labelled magnitude scale (gLMS) and its palatability using the hedonic gLMS. To determine whether GWAS-identified associations with Ace-K generalized to a more complex stimulus, panelists also rated the taste of a pediatric medicine that contains Ace-K as an excipient (Children’s Motrin™). We identified that a TAS2R-containing locus on chromosome 12 was associated with bitterness ratings of Ace-K (p-values < 5 × 10− 8), and the lead SNP rs2708381 in this locus was associated with the sweetness intensity of Children’s Motrin™ (p-value = 0.001). SNP rs2708381 was also associated with perceived intensity ratings of another LCS, neohesperidine dihydrochalcone, in a replication GWAS of 1,757 panelists (p-value = 0.002). A locus within the gene ELMO1, which encodes engulfment and cell motility protein 1, was associated with hedonic ratings of Ace-K (p-values < 5 × 10− 8), and no genome-wide significant signals were observed for sweetness ratings. These findings identify a novel genetic locus containing TAS2R genes that contributes to personal differences in the taste of Ace-K, which may impact the acceptance of medicines, food, and beverages containing Ace-K.

Clinical trials registration: Sensory evaluation of the taste of pediatric medicines (MEDTASTE); clinical trials registry number NCT03627351, registered on 13 August 2018.